Fibrosis-Pipeline Review, H2 2015

Fibrosis-Pipeline Review, H2 2015

  • Products Id :- GMDHC7279IDB
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fibrosis-Pipeline Review, H2 2015


Global Markets Direct's, 'Fibrosis-Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Fibrosis Overview 10

Therapeutics Development 11

Pipeline Products for Fibrosis-Overview 11

Pipeline Products for Fibrosis-Comparative Analysis 12

Fibrosis-Therapeutics under Development by Companies 13

Fibrosis-Therapeutics under Investigation by Universities/Institutes 15

Fibrosis-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Fibrosis-Products under Development by Companies 19

Fibrosis-Products under Investigation by Universities/Institutes 21

Fibrosis-Companies Involved in Therapeutics Development 22

Abeome Corporation 22

Acceleron Pharma, Inc. 23

Complexa, Inc. 24

Digna Biotech, S.L. 25

F. Hoffmann-La Roche Ltd. 26

FibroGen, Inc. 27

GlycoMimetics, Inc. 28

HanAll Biopharma Co., Ltd. 29

Isarna Therapeutics GmbH 30

Lycera Corp. 31

miRagen Therapeutics, Inc. 32

Neumedicines Inc. 33

Ribomic Inc. 34

RuiYi Inc. 35

Scholar Rock, Inc. 36

Siena Biotech S.p.A. 37

Silence Therapeutics Plc 38

SK Chemicals Co., Ltd. 39

UCB S.A. 40

XOMA Corporation 41

Fibrosis-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

ACE-2531-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Antibodies for Fibrosis-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Antibody to Inhibit Transglutaminase 2 for Fibrosis-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

disitertide-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Drug to Activate Insulin Like Growth Factor for Fibrosis-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

G-XXX-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

HL-156FIB-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

IB-DMD-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ISTH-1047-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MGN-4220-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NCE-401-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

NMIL-121-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

NPH-09-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

P-006-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

PRI-724-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

RBM-003-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

RBM-007-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

RG-6069-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

RNAi Oligonucleotide for Liver Diseases-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

RYI-028-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecule to Inhibit LOXL2 for Fibrosis-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Inhibit Rho Kinase for Fibrosis-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecules for Inflammatory Diseases and Fibrosis-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Trophokine-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

XOMA-089-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Fibrosis-Recent Pipeline Updates 90

Fibrosis-Dormant Projects 95

Fibrosis-Dormant Projects 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Tables

Number of Products under Development for Fibrosis, H2 2015 11

Number of Products under Development for Fibrosis-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Comparative Analysis by Unknown Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Fibrosis-Pipeline by Abeome Corporation, H2 2015 22

Fibrosis-Pipeline by Acceleron Pharma, Inc., H2 2015 23

Fibrosis-Pipeline by Complexa, Inc., H2 2015 24

Fibrosis-Pipeline by Digna Biotech, S.L., H2 2015 25

Fibrosis-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 26

Fibrosis-Pipeline by FibroGen, Inc., H2 2015 27

Fibrosis-Pipeline by GlycoMimetics, Inc., H2 2015 28

Fibrosis-Pipeline by HanAll Biopharma Co., Ltd., H2 2015 29

Fibrosis-Pipeline by Isarna Therapeutics GmbH, H2 2015 30

Fibrosis-Pipeline by Lycera Corp., H2 2015 31

Fibrosis-Pipeline by miRagen Therapeutics, Inc., H2 2015 32

Fibrosis-Pipeline by Neumedicines Inc., H2 2015 33

Fibrosis-Pipeline by Ribomic Inc., H2 2015 34

Fibrosis-Pipeline by RuiYi Inc., H2 2015 35

Fibrosis-Pipeline by Scholar Rock, Inc., H2 2015 36

Fibrosis-Pipeline by Siena Biotech S.p.A., H2 2015 37

Fibrosis-Pipeline by Silence Therapeutics Plc, H2 2015 38

Fibrosis-Pipeline by SK Chemicals Co., Ltd., H2 2015 39

Fibrosis-Pipeline by UCB S.A., H2 2015 40

Fibrosis-Pipeline by XOMA Corporation, H2 2015 41

Assessment by Monotherapy Products, H2 2015 42

Number of Products by Stage and Target, H2 2015 44

Number of Products by Stage and Mechanism of Action, H2 2015 46

Number of Products by Stage and Route of Administration, H2 2015 48

Number of Products by Stage and Molecule Type, H2 2015 50

Fibrosis Therapeutics-Recent Pipeline Updates, H2 2015 90

Fibrosis-Dormant Projects, H2 2015 95

List of Figures

Number of Products under Development for Fibrosis, H2 2015 11

Number of Products under Development for Fibrosis-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 42

Number of Products by Top 10 Targets, H2 2015 43

Number of Products by Stage and Top 10 Targets, H2 2015 43

Number of Products by Top 10 Mechanism of Actions, H2 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 45

Number of Products by Routes of Administration, H2 2015 47

Number of Products by Stage and Routes of Administration, H2 2015 47

Number of Products by Top 10 Molecule Types, H2 2015 49

Number of Products by Stage and Top 10 Molecule Types, H2 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Abeome Corporation

Acceleron Pharma, Inc.

Complexa, Inc.

Digna Biotech, S.L.

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

GlycoMimetics, Inc.

HanAll Biopharma Co., Ltd.

Isarna Therapeutics GmbH

Lycera Corp.

miRagen Therapeutics, Inc.

Neumedicines Inc.

Ribomic Inc.

RuiYi Inc.

Scholar Rock, Inc.

Siena Biotech S.p.A.

Silence Therapeutics Plc

SK Chemicals Co., Ltd.


XOMA Corporation

Fibrosis Therapeutic Products under Development, Key Players in Fibrosis Therapeutics, Fibrosis Pipeline Overview, Fibrosis Pipeline, Fibrosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]